

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION</b> IN AN APPLICATION (Use several sheets if necessary) JUN 21 2004			Docket Number (Optional) SPV-048.02		Application Number 10/722,114	
			Applicant Hoemann, Michael Z.			
			Filing Date 11/25/03		Group Art Unit 1625	

### U.S. PATENT DOCUMENTS

EXAMINEE INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RO	AA US 6,211,198	04/2001	Gluchowski et al.	514	318	
RO	AB US 6,159,990	12/2000	Lagu et al.	514	326	
RO	AC US 6,124,319	09/26/00	MacCoss et al.	514	318	
RO	AD US 5,968,955	10/19/99	Mantegani et al.	514	326	
RO	AE US 5,807,865	09/15/98	Harrison et al.	514	278	
RO	AF US 5,118,693	06/02/92	Toth et al.	514	327	
RO	AG US 2,538,107	01/16/51	Kwartler et al.	260	294	
RO	AH US 3,108,111	10/22/63	Stem et al.	260	294.7	
RO	AI US 4,485,109	11/27/84	Ciganek	424	267	

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
RO	AJ WO 94/10165	05/11/94	PCT				X
RO	AK WO 95/19344	07/20/95	PCT				X
RO	AL WO 97/32852	09/12/97	PCT			English Abstract on the first page	
RO	AM WO 99/04794	02/04/99	PCT				X
RO	AN WO 99/58501	11/18/99	PCT				X
RO	AO EP 0 412 822 B1	04/06/94	European Patent Specification				X
RO	AP EP 0 337 167 A1	1/18/89	European Patent Application				X
RO	AQ FR 1.477.152	3/6/67	France				X

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages Etc.)

RO	AR	Brine et al.; "Synthesis of 4,4- Disubstituted Piperidine Analogs of ( $\pm$ )-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3- Methyl-4-piperidyl]-N-phenylpropanamide", Journal of Heterocyclic Chemistry, 31(2):513-520, (Mar-Apr. 1994)
RO	AS	Colapret et al.; "Synthesis and Pharmacological Evaluation of 4,4-Disubstituted Piperidines", J. Med. Chem. 32: 968-974, (1989)
RO	AT	Huegi et al.; "Synthesis and Pharmacological Studies of 4,4-Disubstituted Peperidines: A New Class of Compound with Potent Analgesic Properties", J. Med. Chem. 26: 42-50, (1983)
RO	AU	Lewis et al.; "An Efficient Protocol for the Preparation of Primary Alcohols Bearing a $\beta$ -Chiral Center Via an Oxazolidinone Auxiliary Mediated Resolution, and Application to the Synthesis of 4,4-Disubstituted Piperidine Substance P Antagonist", J. Org. Chem. 65: 2615-2618, (2000)
RO	AV	Huybrechts and Hoornaert; "2-Bromo-N-(2-Bromoethyl)-N-Carbethoxyethanamine, A Useful Reagent in the Synthesis of 4,4 Disubstituted piperidines", Synthetic Communication, 11 (1): 17-23, (1981)

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) SPV-048.02	Application Number 10/722,114
		Applicant Hoemann, Michael Z.	
		Filing Date 11/25/03	Group Art Unit 1625
<i>Re</i>	AW	Stevenson et al.; "4,4-Disubstituted Piperidines: A New Class of NK1 Antagonist", J. Med. Chem. 38: 1264-1266, (1995)	
<i>Re</i>	AX	DeGraw et al.; "Histamine Releasers. III. Dibasic Acid Amides of 4-phenyl-4Aminomethylpiperidines", J. Med. Chem. 10(2): 174-177, (1967)	
<i>Re</i>	AY	Gervais et al.; "Cyclodeshydration D'Alcool Phenol Induite par L'H.M.P.A. Nouvelle voie D'Acces aux Dihydrobenzofurannes et Dihydrobenzopyrannes", Tetrahedron 35: 745-752, (1979)	
<i>Re</i>	AZ	Rehse and Wemer; "Antiaggregatorische and Anticoagulante Eigenschaften von Oligoaminen+ 1 Mitt", Arch. Pharm. 319(6): 505-515, (1986)	
<i>Re</i>	BA	Rehse et al.; "Neuropsychotropo Aktivitat Dopaminanaloger Piperidin-Und Piperazinderivate", Arch. Pharm. (Weinheim) 312:670-681 (1979)	
<i>Re</i>	BB	Stevenson et al.; "4,4-Disubstituted Piperidine High-Affinity NK <sub>1</sub> Antagonists: Structure-Activity Relationships and in Vivo Activity", J. Med. Chem. 41: 4623-4635, (1998)	
<i>Re</i>	BC	Yamato et al.; "Synthesis and Biological Activity of Spiro[isocoumarin-piperidines] and Related Compounds", Chem. Pharm. Bull. 29(2): 402-405, (1981)	
<i>Re</i>	BD	Annex to Form PCT/ISA/206 Showing Partial International Search Report Mailed on July 07, 2002	
EXAMINER	<i>R. Desai</i>		DATE CONSIDERED <i>10/8/04</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE